AstraZeneca Investors Alert: Securities Class Action Lawsuit Announced
New York, NY – In a recent development, Levi & Korsinsky, LLP has announced the filing of a securities class action lawsuit against AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN). The lawsuit alleges securities fraud against the Company and seeks to recover losses on behalf of investors who purchased or otherwise held AstraZeneca securities between February 23, 2022, and December 17, 2024.
Class Definition
The proposed class includes all persons or entities who purchased or otherwise acquired AstraZeneca securities during the Class Period. If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Allegations
The complaint alleges that AstraZeneca made false and/or misleading statements and/or failed to disclose material information during the Class Period. Specifically, the complaint alleges that the Company failed to disclose that its drug, Farxiga, was experiencing safety concerns regarding an increased risk of amputations and that the Company’s clinical trial data was manipulated to conceal these risks.
Impact on Individual Investors
If you invested in AstraZeneca during the Class Period and have suffered losses, you may be entitled to compensation. The investigation seeks to recover damages on behalf of these investors. It is important for investors to protect their rights and interests. If you wish to discuss this action or have any questions about the securities class action, please contact Levi & Korsinsky, LLP.
Impact on the World
The filing of this securities class action lawsuit against AstraZeneca could have significant implications for the pharmaceutical industry as a whole. It sends a message that companies must be transparent about the risks associated with their drugs and that investors deserve accurate information. This lawsuit may also lead to increased scrutiny of other pharmaceutical companies and their clinical trial data.
Conclusion
In summary, Levi & Korsinsky, LLP has announced the filing of a securities class action lawsuit against AstraZeneca PLC, alleging securities fraud between February 23, 2022, and December 17, 2024. The proposed class includes all persons or entities who purchased or otherwise held AstraZeneca securities during this period. If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2025. The allegations include the Company’s failure to disclose safety concerns regarding its drug, Farxiga, and manipulation of clinical trial data. This lawsuit could have significant implications for the pharmaceutical industry and the importance of transparency and accurate information for investors.
- AstraZeneca PLC (“AstraZeneca”)
- Securities Class Action Lawsuit
- February 23, 2022, to December 17, 2024
- Allegations of securities fraud
- Failure to disclose safety concerns regarding Farxiga
- Manipulation of clinical trial data
- Levi & Korsinsky, LLP
- Lead Plaintiff
- April 4, 2025
- Pharmaceutical industry
- Transparency and accurate information
